1. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates.;Nimz;Invest. Ophthalmol. Vis. Sci.,2016
2. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration;Dugel;Ophthalmology,2020
3. HAWK and HARRIER: 96-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration;Dugel;Ophthalmology,2020
4. Beovu® [US prescribing information],2019
5. Beovu® [Swissmedic prescribing information],2020